Kibow Biotech is a biotechnology company founded in 1997, based in suburban Philadelphia, specializing in the development and commercialization of scientifically formulated and clinically-tested natural probiotic health supplements especially for kidney health. Its product Renadyl has three strains of naturally occurring probiotics, to metabolize uremic toxins and restore the healthy gut microbiome. Renadyl has a pharmaceutical-like validation with extensive R&D including SHIME studies, nephrectomized rat and pig studies, animal trials in cats, dogs, and retired zoo animals with kidney failure (lions, tigers, cougars, and sea lions), safety dose-escalation clinical trials in humans, and efficacy clinical trials in CKD and dialysis patient populations with positive outcomes. Renadyl offers safer alternatives to drugs to minimize adverse reactions and side effects. Kibow’s mission is to provide inexpensive, convenient, and efficacious kidney health supplements to CKD patients worldwide.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Live Bio-therapeutic Drug Product
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):